Houlihan Lokey Advises Orsini Specialty Pharmacy

Houlihan Lokey is pleased to announce that Orsini Specialty Pharmacy (Orsini), a portfolio company of Consonance Capital Partners, has entered into a partnership with Carlyle. This transaction closed on May 2, 2022.

Headquartered in Elk Grove Village, Illinois, Orsini is the leading independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions. Providing patients with comprehensive and compassionate care since 1987, Orsini’s high-touch care model centers around experienced, therapy-specific teams that provide personalized care to patients based on their specific conditions and treatments. The company’s comprehensive solutions include medication adherence programs, data analytics, customized manufacturer programs, and nationwide nursing coverage for convenient in-home infusion services.

Consonance Capital Partners invests in private companies in the middle market of the U.S. healthcare industry with an emphasis on businesses driving efficiency, cost containment, and high-quality clinical care to patients. Consonance Capital Partners participates in growth equity, leveraged buyout, and recapitalization transactions.

Carlyle (NASDAQ:CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: global private equity, global credit, and global investment solutions. With $325 billion of assets under management as of March 31, 2022, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which they live and invest. Carlyle employs nearly 1,900 people in 26 offices across five continents.

Houlihan Lokey served as the exclusive financial advisor to Orsini and assisted in initiating, structuring, and negotiating the transaction on its behalf.

This transaction further strengthens and highlights Houlihan Lokey’s continued leadership position in pharmacy services. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the country. In 2021, the group closed more than 60 transactions and was ranked the No. 1 M&A advisor for global healthcare transactions under $1 billion by Refinitiv*.

*Excludes accounting firms and brokers.